SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study
| العنوان: | SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study |
|---|---|
| المؤلفون: | Alessandro Sciarra, Daniela Terracciano, Angelo Porreca, Giuseppe Lucarelli, Rosario Leonardi, Francesco Del Giudice, Gian Maria Busetto, Martina Maggi, Matthew R. Cooperberg, Ugo Falagario, Luigi Cormio, Giuseppe Carrieri, Giuseppe Salvatore Sepe, Giorgio Ivan Russo, Peter R. Carroll, Ettore De Berardinis, Andrea Cocci, Fabio Galasso, Marina Di Mauro, Gabriele Iacona, Matteo Ferro |
| المساهمون: | Maggi, Martina, Del Giudice, Francesco, Falagario, Ugo G, Cocci, Andrea, Russo, Giorgio Ivan, Di Mauro, Marina, Sepe, Giuseppe Salvatore, Galasso, Fabio, Leonardi, Rosario, Iacona, Gabriele, Carroll, Peter R, Cooperberg, Matthew R, Porreca, Angelo, Ferro, Matteo, Lucarelli, Giuseppe, Terracciano, Daniela, Cormio, Luigi, Carrieri, Giuseppe, De Berardinis, Ettore, Sciarra, Alessandro, Busetto, Gian Maria |
| المصدر: | Cancers Cancers, Vol 13, Iss 2047, p 2047 (2021) Volume 13 Issue 9 Cancers, vol 13, iss 9 |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Urologic Diseases, Aging, Cancer Research, medicine.medical_specialty, Prostate biopsy, Oncology and Carcinogenesis, 030232 urology & nephrology, Article, magnetic resonance, 03 medical and health sciences, Prostate cancer, PSA, 0302 clinical medicine, Clinical Research, Prostate, Biopsy, medicine, urinary biomarker, prostate biopsy, Overdiagnosis, early detection, RC254-282, Cancer, screening and diagnosis, medicine.diagnostic_test, business.industry, Prostate Cancer, biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Magnetic resonance imaging, medicine.disease, prostate cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, medicine.anatomical_structure, Oncology, prostate neoplasm, 030220 oncology & carcinogenesis, Biomarker (medicine), Prostate neoplasm, Radiology, mpMRI, business, 4.2 Evaluation of markers and technologies |
| الوصف: | Simple Summary Prostate-specific antigen and digital rectal examination, used to guide prostate biopsy, often result in overdiagnosis of indolent prostate cancer (PCa) while missing clinically significant PCa (csPCa). The aim of this study was to evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance imaging (mpMRI) in predicting PCa in prostate biopsies. SelectMDx was revealed to be a good predictor of PCa, while with regards to csPCa detection, it was demonstrated to be less effective, showing results similar to mpMRI. The best diagnostic strategy to avoid unnecessary biopsy is performing SelectMDx after an initial negative mpMRI. Biopsy could be proposed for all cases of positive mpMRI and to those with a negative mpMRI followed by a positive SelectMDx. Abstract Prostate-specific antigen (PSA) testing as the sole indication for prostate biopsy lacks specificity, resulting in overdiagnosis of indolent prostate cancer (PCa) and missing clinically significant PCa (csPCa). SelectMDx is a biomarker-based risk score to assess urinary HOXC6 and DLX1 mRNA expression combined with traditional clinical risk factors. The aim of this prospective multi-institutional study was to evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance (mpMRI) when predicting PCa in prostate biopsies. Overall, 310 consecutive subjects were included. All patients underwent mpMRI and SelectMDx prior to prostate biopsy. SelectMDx and mpMRI showed sensitivity and specificity of 86.5% vs. 51.9%, and 73.8% vs. 88.3%, respectively, in predicting PCa at biopsy, and 87.1% vs. 61.3%, and 63.7% vs. 83.9%, respectively, in predicting csPCa at biopsy. SelectMDx was revealed to be a good predictor of PCa, while with regards to csPCa detection, it was demonstrated to be less effective, showing results similar to mpMRI. With analysis of strategies assessed to define the best diagnostic strategy to avoid unnecessary biopsy, SelectMDx appeared to be a reliable pathway after an initial negative mpMRI. Thus, biopsy could be proposed for all cases of mpMRI PI-RADS 4–5 score, and to those with Prostate Imaging-Reporting and Data System (PI-RADS) 1–3 score followed by a positive SelectMDx. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c98dfc0454ea4c5d904c5146f8f0b3 http://europepmc.org/articles/PMC8122883 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....f3c98dfc0454ea4c5d904c5146f8f0b3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|